Cargando…

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality

BACKGROUND: Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly h...

Descripción completa

Detalles Bibliográficos
Autores principales: Neutzsky-Wulff, Anita V, Sørensen, Mette G, Kocijancic, Dino, Leeming, Diana J, Dziegiel, Morten H, Karsdal, Morten A, Henriksen, Kim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891608/
https://www.ncbi.nlm.nih.gov/pubmed/20515459
http://dx.doi.org/10.1186/1471-2474-11-109
_version_ 1782182874366083072
author Neutzsky-Wulff, Anita V
Sørensen, Mette G
Kocijancic, Dino
Leeming, Diana J
Dziegiel, Morten H
Karsdal, Morten A
Henriksen, Kim
author_facet Neutzsky-Wulff, Anita V
Sørensen, Mette G
Kocijancic, Dino
Leeming, Diana J
Dziegiel, Morten H
Karsdal, Morten A
Henriksen, Kim
author_sort Neutzsky-Wulff, Anita V
collection PubMed
description BACKGROUND: Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human osteoclasts with different inhibitors and characterized their resulting function. METHODS: Human CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification (bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, CTX-I and ICTP, as well as by counting resorption pits. RESULTS: All inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-100 μM], however, this treatment dramatically reduced TRACP activity. CONCLUSIONS: We present evidence highlighting important differences with respect to osteoclast function, when comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations in osteoclast quality, which secondarily may lead to different bone qualities.
format Text
id pubmed-2891608
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28916082010-06-25 Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality Neutzsky-Wulff, Anita V Sørensen, Mette G Kocijancic, Dino Leeming, Diana J Dziegiel, Morten H Karsdal, Morten A Henriksen, Kim BMC Musculoskelet Disord Research article BACKGROUND: Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human osteoclasts with different inhibitors and characterized their resulting function. METHODS: Human CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification (bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, CTX-I and ICTP, as well as by counting resorption pits. RESULTS: All inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-100 μM], however, this treatment dramatically reduced TRACP activity. CONCLUSIONS: We present evidence highlighting important differences with respect to osteoclast function, when comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations in osteoclast quality, which secondarily may lead to different bone qualities. BioMed Central 2010-06-01 /pmc/articles/PMC2891608/ /pubmed/20515459 http://dx.doi.org/10.1186/1471-2474-11-109 Text en Copyright ©2010 Neutzsky-Wulff et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research article
Neutzsky-Wulff, Anita V
Sørensen, Mette G
Kocijancic, Dino
Leeming, Diana J
Dziegiel, Morten H
Karsdal, Morten A
Henriksen, Kim
Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title_full Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title_fullStr Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title_full_unstemmed Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title_short Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
title_sort alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
topic Research article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891608/
https://www.ncbi.nlm.nih.gov/pubmed/20515459
http://dx.doi.org/10.1186/1471-2474-11-109
work_keys_str_mv AT neutzskywulffanitav alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT sørensenmetteg alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT kocijancicdino alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT leemingdianaj alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT dziegielmortenh alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT karsdalmortena alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality
AT henriksenkim alterationsinosteoclastfunctionandphenotypeinducedbydifferentinhibitorsofboneresorptionimplicationsforosteoclastquality